WallStreetZenWallStreetZen

NASDAQ: AVTX
Avalo Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for AVTX

Based on 9 analysts offering 12 month price targets for Avalo Therapeutics Inc

Min Forecast
$39.00+95.59%
Avg Forecast
$49.89+150.2%
Max Forecast
$62.00+210.93%

Should I buy or sell AVTX stock?

Based on 9 analysts offering ratings for Avalo Therapeutics Inc.

Strong Buy
Strong Buy
3 analysts 33.33%
Buy
6 analysts 66.67%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although AVTX's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates AVTX as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their AVTX stock forecasts and price targets.

AVTX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-05-11Find Out Why
lockedlocked$00.00+00.00%2026-05-06
lockedlocked$00.00+00.00%2026-05-06
lockedlocked$00.00+00.00%2026-05-06Find Out Why
lockedlocked$00.00+00.00%2026-04-09
Citizens
Top 2%
99
BuyInitiates Coverage On$52.00+160.78%2026-04-06
HC Wainwright & Co.
Top 8%
93
BuyMaintains$40.00+100.60%2026-03-25
Guggenheim
Top 2%
99
Strong BuyInitiates Coverage On$50.00+150.75%2026-02-02
Mizuho
Top 26%
75
BuyInitiates Coverage On$39.00+95.59%2025-12-18

1 of 1

Forecast return on equity

Is AVTX forecast to generate an efficient return?

Company
-94.6%
Industry
75.1%
Market
170.33%
AVTX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is AVTX forecast to generate an efficient return on assets?

Company
-67.46%
Industry
28.98%
AVTX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

AVTX earnings per share forecast

What is AVTX's earnings per share in the next 3 years based on estimates from 14 analysts?

Avg 1 year Forecast
-$3.44
Avg 2 year Forecast
-$3.75
Avg 3 year Forecast
-$4.15

AVTX revenue forecast

What is AVTX's revenue in the next 3 years based on estimates from 12 analysts?

Avg 1 year Forecast
$0.0-100%
Avg 2 year Forecast
$0.0-100%
Avg 3 year Forecast
$0.0-100%
AVTX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

AVTX revenue growth forecast

How is AVTX forecast to perform vs Biotechnology companies and vs the US market?

Company
-100%
Industry
33.66%
Market
13.98%
AVTX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
AVTX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

AVTX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
AVTX$19.94$49.89+150.20%Strong Buy
ZURA$4.75$14.75+210.53%Strong Buy
LYEL$19.25$41.00+112.99%Buy
LXEO$5.70$17.75+211.40%Strong Buy
FULC$6.96$17.83+156.22%Buy
View Top Biotech Stocks

Avalo Therapeutics Stock Forecast FAQ

Is Avalo Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 9 Wall Street analysts covering (NASDAQ: AVTX) stock is to Strong Buy AVTX stock.

Out of 9 analysts, 3 (33.33%) are recommending AVTX as a Strong Buy, 6 (66.67%) are recommending AVTX as a Buy, 0 (0%) are recommending AVTX as a Hold, 0 (0%) are recommending AVTX as a Sell, and 0 (0%) are recommending AVTX as a Strong Sell.

If you're new to stock investing, here's how to buy Avalo Therapeutics stock.

What is AVTX's earnings growth forecast for 2026-2028?

(NASDAQ: AVTX) Avalo Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.2%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.27%.

Avalo Therapeutics's earnings in 2026 is -$78,259,000.On average, 14 Wall Street analysts forecast AVTX's earnings for 2026 to be -$78,362,650, with the lowest AVTX earnings forecast at -$89,777,385, and the highest AVTX earnings forecast at -$44,266,568. On average, 11 Wall Street analysts forecast AVTX's earnings for 2027 to be -$85,438,464, with the lowest AVTX earnings forecast at -$109,430,147, and the highest AVTX earnings forecast at -$31,824,073.

In 2028, AVTX is forecast to generate -$94,510,547 in earnings, with the lowest earnings forecast at -$126,849,639 and the highest earnings forecast at -$39,002,436.

What is AVTX's revenue growth forecast for 2026-2028?

(NASDAQ: AVTX) Avalo Therapeutics's forecast annual revenue growth rate of -100% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.66%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.98%.

Avalo Therapeutics's revenue in 2026 is $59,000.On average, 12 Wall Street analysts forecast AVTX's revenue for 2026 to be $0, with the lowest AVTX revenue forecast at $0, and the highest AVTX revenue forecast at $0. On average, 9 Wall Street analysts forecast AVTX's revenue for 2027 to be $0, with the lowest AVTX revenue forecast at $0, and the highest AVTX revenue forecast at $0.

In 2028, AVTX is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is AVTX's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: AVTX) forecast ROA is -67.46%, which is lower than the forecast US Biotechnology industry average of 28.98%.

What is AVTX's Price Target?

According to 9 Wall Street analysts that have issued a 1 year AVTX price target, the average AVTX price target is $49.89, with the highest AVTX stock price forecast at $62.00 and the lowest AVTX stock price forecast at $39.00.

On average, Wall Street analysts predict that Avalo Therapeutics's share price could reach $49.89 by May 11, 2027. The average Avalo Therapeutics stock price prediction forecasts a potential upside of 150.2% from the current AVTX share price of $19.94.

What is AVTX's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: AVTX) Avalo Therapeutics's current Earnings Per Share (EPS) is -$5.84. On average, analysts forecast that AVTX's EPS will be -$3.44 for 2026, with the lowest EPS forecast at -$3.94, and the highest EPS forecast at -$1.94. On average, analysts forecast that AVTX's EPS will be -$3.75 for 2027, with the lowest EPS forecast at -$4.80, and the highest EPS forecast at -$1.40. In 2028, AVTX's EPS is forecast to hit -$4.15 (min: -$5.57, max: -$1.71).

What is AVTX's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: AVTX) forecast ROE is -94.6%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.